Literature DB >> 20105171

Molecular epidemiology of erythropoietic protoporphyria in the U.K.

S D Whatley1, N G Mason, S A Holme, A V Anstey, G H Elder, M N Badminton.   

Abstract

BACKGROUND: Erythropoietic protoporphyria (EPP) is a cutaneous porphyria caused by mutations in the ferrochelatase (FECH) or, less frequently, the delta-aminolaevulinate synthase 2 (ALAS2) gene. Predictive genetic counselling requires accurate molecular diagnosis and knowledge of patterns of inheritance.
OBJECTIVES: To investigate the molecular epidemiology of EPP in the U.K.
METHODS: DNA samples from 191 unrelated patients resident in the U.K. were analysed for mutations in the FECH and ALAS2 genes and for the FECH IVS3-48 dimorphism.
RESULTS: Mutations were identified in 179 (94%) patients. Most (169; 94%) had a FECH mutation on one allele and were classified as having pseudodominant EPP (psdEPP); seven (4%) patients had FECH mutations on both alleles (autosomal recessive EPP) and three (2%) patients had ALAS2 mutations (X-linked dominant protoporphyria). The FECH IVS3-48C allele was strongly associated with psdEPP and with the absence of mutations at the FECH or ALAS2 loci. Fifty-six FECH mutations were identified, 19 being previously unreported. Missense mutations were predominant in autosomal recessive EPP (82%) but not in psdEPP (32%). One mutation (c.314 + 2T>G) was present in 41 (24%) of EPP families, most of whom appeared to be descended from a common ancestor resident in the north of England.
CONCLUSIONS: These data define the prevalence and molecular epidemiology of each type of EPP in the U.K.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20105171     DOI: 10.1111/j.1365-2133.2010.09631.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

1.  Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.

Authors:  Vincent Oustric; Hana Manceau; Sarah Ducamp; Rima Soaid; Zoubida Karim; Caroline Schmitt; Arienne Mirmiran; Katell Peoc'h; Bernard Grandchamp; Carole Beaumont; Said Lyoumi; François Moreau-Gaudry; Véronique Guyonnet-Dupérat; Hubert de Verneuil; Joëlle Marie; Herve Puy; Jean-Charles Deybach; Laurent Gouya
Journal:  Am J Hum Genet       Date:  2014-03-27       Impact factor: 11.025

2.  Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.

Authors:  Manisha Balwani; Hetanshi Naik; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Jessica R Overbey; Bruce Wang; Ashwani K Singal; Lawrence U Liu; Robert J Desnick
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

3.  Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity.

Authors:  Jasmin Barman-Aksoezen; Domenico Girelli; Caterina Aurizi; Xiaoye Schneider-Yin; Natascia Campostrini; Luca Barbieri; Elisabeth I Minder; Gianfranco Biolcati
Journal:  J Inherit Metab Dis       Date:  2017-02-09       Impact factor: 4.982

4.  The incidence of inherited porphyrias in Europe.

Authors:  George Elder; Pauline Harper; Michael Badminton; Sverre Sandberg; Jean-Charles Deybach
Journal:  J Inherit Metab Dis       Date:  2012-11-01       Impact factor: 4.982

5.  Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrias.

Authors:  Eric W Gou; Manisha Balwani; D Montgomery Bissell; Joseph R Bloomer; Herbert L Bonkovsky; Robert J Desnick; Hetanshi Naik; John D Phillips; Ashwani K Singal; Bruce Wang; Sioban Keel; Karl E Anderson
Journal:  Clin Chem       Date:  2015-10-19       Impact factor: 8.327

Review 6.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

Review 7.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

8.  Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.

Authors:  Manisha Balwani; Dana Doheny; David F Bishop; Irina Nazarenko; Makiko Yasuda; Harry A Dailey; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Lawrence Liu; Robert J Desnick
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

Review 9.  The porphyrias: advances in diagnosis and treatment.

Authors:  Manisha Balwani; Robert J Desnick
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

Review 10.  Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

Authors:  Ashley M Lane; Jerome T McKay; Herbert L Bonkovsky
Journal:  Appl Clin Genet       Date:  2016-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.